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Abstract
Rationale: Pneumonia due to Pseudomonas aeruginosa (PA) is
associated with high mortality and requires antipseudomonal
treatment. Because PA can colonize the respiratory tract, the
diagnosis of pathogenic PA involvement is challenging.
Objectives: To determine the prevalence of definitive and
indeterminate PA infection in community-acquired pneumonia, to
describe the clinical and microbiological profiles, and to estimate the
burden of unnecessary antipseudomonal drug prescriptions.
Methods: We prospectively enrolled 2,701 patients with
community-acquired pneumonia. Using stringent criteria for
diagnosing PA pneumonia, we generated the following three groups:
1) definitive PA, 2) indeterminate PA, and 3) non-PA pneumonia.
Results: The prevalence of definitive PA pneumonia was 0.9%
(n 5 25), and that of indeterminate PA pneumonia was 4.9%
(n 5 131). Considerable clinical differences were observed among
the groups. Patients with definitive PA pneumonia were more
likely to have a history of tuberculosis and chronic obstructive
pulmonary disease/bronchiectasis and had a higher 30-day
mortality (28%) than patients with non-PA pneumonia. Patients
with indeterminate PA pneumonia were more likely to have
comorbidities than patients with non-PA pneumonia. More than
half of the patients with indeterminate PA and 25% of the
patients with non-PA pneumonia were treated with an
antipseudomonal drug. No patients with definitive PA
pneumonia had multidrug resistance.
Conclusions: In this population, the prevalence of community-
acquired pneumonia due to PA was low. The clinical features and
30-day mortality rates of patients with indeterminate PA pneumonia
were different from those of patients with definitive PA pneumonia.
Most of the prescribed antipseudomonal drugs for patients with
community-acquired pneumonia were potentially unnecessary.
Keywords: adult pneumonia; Pseudomonas aeruginosa;
community-acquired pneumonia
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Pseudomonas aeruginosa (PA), an aerobic
and gram-negative rod-shaped bacterium, is
ubiquitous and one of the most common
pathogens isolated from patients with
hospital-acquired pneumonia (1, 2).
Although community-acquired pneumonia
(CAP) due to PA is rare, PA is an
independent risk factor associated with high
30-day mortality (3–5). Pneumonia due to
PA (definitive PA pneumonia)
is associated with prolonged
hospitalization in the intensive care
unit and extra costs (2, 6).
Antipseudomonal drugs are required
for the initial treatment of PA pneumonia (2,
7). Because there is no consensus on the
diagnostic criteria for PA pneumonia, the
individual risk factors for PA vary across
studies (8). The 2019 American Thoracic
Society (ATS)/Infectious Diseases Society of
America (IDSA) guideline recommends
initiating antipseudomonal drugs after
considering the local epidemiology and
validated risk factors for culture-positive PA
pneumonia, such as prior infection, recent
hospitalization, and the use of parenteral
antibiotics in the last 90 days (8). However,
von Baum and colleagues (9) reported that
approximately 1% of patients with CAP were
culture positive for PA, of whom only 45%
were regarded as having definitive PA
pneumonia in Germany. Because of the
small sample size, they did not conclusively
determine which factors can differentiate
definitive PA pneumonia from other cases of
culture-positive PA pneumonia
(indeterminate PA pneumonia). In Japan,
PA was isolated from 3% to 6% of patients
with CAP, but there are no data on the
proportion of definitive PA pneumonia in
this group (10, 11). Thus, the current
practices regarding pneumonia treatment
may lead to the overdiagnosis of PA
pneumonia, resulting in overtreatment with
antipseudomonal drugs (2). To avoid the
unnecessary use of antipseudomonal drugs
for nondefinitive PA pneumonia (i.e.,
indeterminate PA pneumonia and culture-
negative PA pneumonia), clarification is
needed regarding the clinical features of both
groups.
Herein, we conducted this study to 1)
determine the prevalence of definitive and
indeterminate PA pneumonia among
patients with CAP, 2) describe the clinical
andmicrobiological profiles of definitive PA
and indeterminate PA pneumonia, and 3)
estimate the burden of unnecessary
antipseudomonal drug prescriptions and
describe the drug susceptibility of PA in
Japan.
Methods
Study Design, Participants, and
Data Collection
The current study was performed as part of
the Adult Pneumonia Study Group-Japan
(APSG-J), a multicenter prospective hospital-
based surveillance for CAP in Japan. The
APSG-J study enrolled 3,509 patients with
pneumonia at four community-based acute
hospitals in Japan from 28 September 2011
to 23 August 2014. For the current study, we
included patients with pneumonia who had
been enrolled in two community-based
referral hospitals (KamedaMedical Center
and Chikamori Hospital). A detailed
description of the APSG-J methodology has
been provided elsewhere (12). Briefly, all
inpatients and outpatients were screened by
hospital physicians, and eligible patients were
identified using the following standardized
case definition: patients aged>15 years with
respiratory symptoms compatible with
pneumonia (i.e., fever, chills or rigors, cough,
sputum, pleuritic chest pain, dyspnea, and/or
tachypnea) and new pulmonary infiltrates on
chest X-ray or computed tomographic
imaging. If a patient developed the disease
more than 48 hours after hospitalization, the
patient was classified as having hospital-
acquired pneumonia and was not enrolled.
Demographic and clinical information was
collected through direct interviews with
patients or their guardians and from reviews
of medical charts using standardized data
collection forms. Using the medical records,
we defined oral steroid or
immunosuppressant use as present
regardless of dosage and defined chronic
obstructive pulmonary disease (COPD) or
bronchiectasis as present regardless of
severity. For this study, further drug
susceptibility in patients with pneumonia
with PA was also collected at these study
hospitals. Although antibiotic selection
should be consistent with the guidelines,
physicians can unrestrictedly prescribe
antipseudomonal drugs in Japan.
Sample Processing and Definitions
All clinical specimens (i.e., respiratory
specimens and blood cultures) were
immediately transported to the
microbiology laboratory at each hospital.
Gram staining and culture were performed
for all available respiratory samples, which
were examined by semiquantitative or
quantitative culture methods. PA isolates
were considered definite causative
pathogens when the following criteria were
fulfilled: 1) PA was isolated from blood
cultures and/or 2) a good-quality sputum
sample (.25 polymorphonuclear cells and
,10 epithelial cells per low-power field
[total magnification,3100]) containing
gram-negative rods likely corresponding
with PA with predominant growth in a
culture of>13 106 cfu/ml (9) or a score
of 31 in a semiquantitative evaluation.
Indeterminate PA was defined when PA
was isolated from the sputum, but the
criteria for definitive PA were not fulfilled.
If PA was not isolated, the case was
characterized as non-PA pneumonia. Drug
susceptibility testing was performed
according to the local protocol for
minimum inhibitory concentration
breakpoints and Clinical and Laboratory
Standards Institute guidelines to
determine antibiotic resistance. Antibiotic
resistance to antipseudomonal drugs was
evaluated (see Table E1 in the online
supplement), and the resistance of PA was
defined as follows: 1) if the isolate was
resistant to at least one of the evaluated
antibiotics, the PA was considered to be
nonsusceptible and defined as drug
resistant or 2) if the isolate was not
susceptible to one or more antibiotic in
three or more antipseudomonal categories,
the PA was defined as multidrug resistant
(MDR) (13). We defined overuse of
antipseudomonal drugs if the physician
did not de-escalate the antipseudomonal
drug adequately referring to the sputum
culture and Gram stain results.
Statistical Analysis
Patients were categorized into three groups
according to PA culture positivity status (i.e.,
definitive PA, indeterminate PA, and non-
PA). Multinomial logistic regression models
were used to explore the factors associated
with the three groups. For comparisons of
definitive PA and non-PA pneumonia and of
indeterminate PA and non-PA pneumonia,
non-PA pneumonia was used as a baseline
group. All samples were included in each
model, and unadjusted and adjusted odds
ratios and 95% confidence intervals were
calculated. On the basis of clinical
experience, we adjusted for age, sex, nursing
home residency, COPD, past history of
pneumonia, and CURB-65 scores in each
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model. CURB-65 scores (Confusion,Urea
.7 mmol/l,Respiratory rate>30/min, low
systolic (,90 mmHg) or diastolic (<60 mm
Hg) Blood pressure, age>65 years) was
calculated and one point given for each
feature present. The treatment duration was
compared using theMann-WhitneyU test.
We accounted for missing data for covariates
by using multiple imputations in all
regression analyses (14). A P value of less
than 0.05 was defined as statistically
significant. All analyses were performed with
Stata, version 14.0 (STATACorp).
Ethics
This study was approved by the institutional
review boards of the Institute of Tropical
Medicine, Nagasaki University (number
11063070), KamedaMedical Center
(number 11–025), and Chikamori Hospital
(number 85). Written informed consent was
obtained from the majority of the
participants or their guardians. The
requirement for obtaining written consent
from all participants was waived by all
institutional review boards because of the
study’s observational nature, with no
deviation from current medical




A total of 2,972 patients with CAP visited the
two study hospitals. Of these, 271 patients
were excluded for the following reasons:
duplication (n5 1), refusal to participate in
the study (n5 5), nonpneumonia diagnosis
(n5 115), and the absence of pulmonary
infiltrates (n5 150). After exclusion, 2,701
patients were eligible for our analysis
(Figure 1).
Among the 2,701 patients with
pneumonia, PA was isolated from 156
patients; definitive and indeterminate PA
pneumonia were diagnosed in 25 (0.9%) and
131 (4.9%) patients, respectively. Of the
definitive PA strains, three were isolated
from blood culture. The baseline clinical
characteristics of the three groups, definitive
PA, indeterminate PA, and non-PA
pneumonia (n5 2,545), are summarized in
Table 1. Approximately 40% of the
participants were female. The median age
was 76 years (interquartile range, 64–84 yr),
and 72% of the patients were older than 65
years. A past history of tuberculosis was
identified in 16% of the patients with
definitive PA pneumonia but in only 3% and
4% of the patients with indeterminate PA
and non-PA pneumonia, respectively.
Chronic lung injury such as COPD/
bronchiectasis was observed in 56% of
patients with definitive PA pneumonia
and in 31% of patients with indeterminate
PA pneumonia, although it was observed
in only 20% of patients with non-PA
pneumonia.
The factors associated with the PA
categories were examined by adjusted
multinomial regression (Table E2). The
patients with definitive PA pneumonia were
more likely to have a history of tuberculosis
and COPD/bronchiectasis than the patients
with non-PA pneumonia. The patients with
indeterminate PA and non-PA pneumonia
showed considerable clinical differences.
Although the proportion of older patients
was similar, the patients with indeterminate
PA pneumonia were more likely than
patients with non-PA pneumonia to be
nursing home residents; to receive on oral
steroids; to have neuromuscular disease, a
low body mass index, a prior hospitalization
in the last 90 days, a history of pneumonia,
vital sign abnormality (i.e., body temperature
<34.9C or>40C), hypoalbuminemia; and
to require help with activities of daily living.
In contrast, patients with indeterminate PA
pneumonia were less likely than patients
Enrolled through hospital record screening
N = 1,334





N = 25 (0.9%)
Indeterminate PA pneumonia
N = 131 (4.9%)
PA isolated
N = 156 (5.8%)
Non-PA pneumonia
N = 2,545 (94.2%)
    1: Duplication
    5: Refusal to consent
115: Non-pneumonia diagnosis
150: No pulmonary infiltrates
Did not meet criteria
N = 271
Figure 1. Study flow diagram. PA5Pseudomonas aeruginosa.
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The treatment and prognosis of each group
are shown in Table 2 (unadjusted model is
shown in Table E3). Patients with
indeterminate PA pneumonia were more
likely to be hospitalized than patients with
non-PA pneumonia. Higher proportions of
patients with definitive PA (80%) and
indeterminate PA (58%) pneumonia were
initially treated with an antipseudomonal
drug than those with non-PA pneumonia
(25%) (see Table E4). Among the patients
with indeterminate PA pneumonia, 76 (58%)
were treated with antipseudomonal drugs,
and 13 who were treated with
nonantipseudomonal drugs were regarded
by physicians as failing to respond to
treatment. The median treatment duration
was longer for patients with definitive PA
pneumonia (median, 10 d; interquartile
range, 6–18 d) and indeterminate PA
pneumonia (median, 13 d; interquartile
range, 7–14 d) than for those with non-PA
pneumonia (median, 7 d; interquartile range,
6–11 d) (P5 0.046 and P, 0.001,
respectively). The use of two
antipseudomonal antibiotics for PA
pneumonia was quite rare in both definitive
PA (8%) and indeterminate PA (2%)
pneumonia cases in our study. Patients with
definitive PA pneumonia were more likely to
need ventilator support and vasopressor
administration than patients with non-PA
pneumonia. In addition to PA, other
pathogens were isolated in definitive PA (8%)
and indeterminate PA (36%) pneumonia
cases (see Table E5). Of the latter group, the
most frequently isolated pathogen other than
PAwas Streptococcus pneumoniae (7%),
followed byHaemophilus influenzae (7%),
Moraxella catarrhalis (5%), andmethicillin-
susceptible Staphylococcus aureus (5%).
In the acute phase, the case fatality rates
of patients with definitive PA pneumonia at
14 days and 30 days (24% and 28%,
respectively) were significantly higher than
those of patients with non-PA pneumonia
(4% and 5%, respectively), although the rates
of patients with indeterminate PA
pneumonia did not differ from those of
patients with non-PA pneumonia.
Overall, antipseudomonal drugs were
prescribed to 741 of the 2,701 (27.4%)
patients with pneumonia. Among
these 741 patients, 20 (2.7%) had
definitive PA pneumonia, and




The drug susceptibility of the PA isolates is
shown in Table 3. Four patients with
definitive PA and eight patients with
indeterminate PA had drug resistance. Of
these, no patients with definitive PA
pneumonia and four patients with
indeterminate PA pneumonia hadMDR PA;
Table 1. Clinical characteristics of patients with definitive PA, indeterminate PA, and non-PA pneumonia
Variable
Culture Positive for PA
Culture Negative for PA
Non-PA Pneumonia (n 5 2,545)Definitive PA (n 5 25) Indeterminate PA (n 5 131)
Sociodemographic characteristics
Age .65 yr 20 (80) 100 (76) 1,836 (72)
Sex, M 15 (60) 87 (66) 1,522 (60)
Nursing home resident 3 (12) 32 (24) 334 (13)
Comorbidities
Hypertension 10 (40) 38 (29) 1,070 (42)
Diabetes 6 (24) 32 (24) 539 (21)
Collagen vascular disease 5 (20) 19 (15) 173 (7)
Neuromuscular disease 2 (8) 24 (18) 165 (6)
Past history of tuberculosis 4 (16) 4 (3) 112 (4)
COPD/bronchiectasis 14 (56) 40 (31) 500 (20)
Body mass index, 0–18.49 7 (28) 48 (37) 563 (22)
Performance status >2 4 (16) 57 (44) 419 (16)
Home oxygen therapy 6 (24) 24 (18) 114 (4)
Medications before hospitalization
Chronic oral steroids 3 (12) 15 (11) 151 (6)
Inhaled corticosteroids 1 (4) 6 (5) 199 (8)
Immunosuppressants 0 (0) 4 (3) 37 (1)
Prior hospitalization* 6 (24) 44 (36) 402 (16)
History of pneumonia 9 (36) 56 (43) 443 (17)
Clinical presentation
Aspiration episode 2 (8) 32 (24) 423 (17)
Temperature, <34.9C or >40C 1 (4) 9 (7) 46 (2)
Albumin, ,3.5 g/dl 13 (52) 82 (63) 1,159 (46)
Chest radiograph findings
X-ray, bilateral infiltration 5 (20) 26 (20) 385 (15)
Pleural effusion 1 (4) 6 (5) 127 (5)
CURB-65, >3 5 (20) 41 (31) 573 (23)
Definition of abbreviations: COPD 5 chronic obstructive pulmonary disease; PA 5 Pseudomonas aeruginosa.
Data are presented as n (%). CURB-65 scores (Confusion, Urea .7 mmol/l, Respiratory rate >30/min, low systolic (,90 mm Hg) or diastolic
(<60 mm Hg) Blood pressure, age >65 years) was calculated and one point given for each feature present.
*Hospitalization >2 days in the last 90 days.
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no isolates from patients with definitive PA
pneumonia and only one isolate from a
patient with indeterminate PA
pneumonia showed resistance to
carbapenems. Most isolates from patients
with definitive PA pneumonia (80%) and
indeterminate PA pneumonia (89%) were
pansusceptible to all antipseudomonal
antibiotics.
Discussion
We demonstrated that only 0.9% of CAP was
due to PA, and that patients with definitive
PA pneumonia had a higher 30-day
mortality rate (28%) than those with non-PA
pneumonia. The clinical features were
considerably different among the patients in
the different PA categories. Patients with
definitive PA pneumonia were more likely to
have a history of tuberculosis and COPD/
bronchiectasis than patients with non-PA
pneumonia. Furthermore, patients with
indeterminate PA pneumonia were more
likely to be frail, older adults with
comorbidities than patients with non-PA
pneumonia. More than half of the patients
with indeterminate PA pneumonia and 25%
of the patients with non-PA pneumonia were
treated with an antipseudomonal drug.
The proportion of patients with PA
infection has varied in previous studies. Our
findings are in line with those of a
multicenter study conducted in Germany by
von Baum and colleagues (9) and those of a
single-center study conducted in Spain by
Cilloniz and colleagues (5), which reported
that 0.4% (n5 22/5,130) and 1.4% (n5 77/
5,384) of patients with CAP were classified as
having definitive PA pneumonia,
respectively. However, in a multicenter study
in 54 countries, Restrepo and colleagues (15)
reported that the prevalence of CAP due to
PA was 4.2% (n5 133/3,193). The higher
prevalence observed by Restrepo and
colleagues (15) may be explained by different
definitions of PA. They did not distinguish
definitive PA pneumonia from
indeterminate PA pneumonia among
patients with CAP with positive PA isolates.
If PA pneumonia is defined on the basis of
only the isolation of PA from a sputum
sample, PA colonization cases are very likely
to be included (2). To identify definitive PA
pneumonia, we used stringent criteria and
classified PA pneumonia into two groups
(definitive PA and indeterminate PA
pneumonia) (9). We found that the majority
of CAP cases with isolated PA were classified
as indeterminate PA pneumonia, suggesting
that the prevalence of true PA pneumonia
may have been overestimated. In the 2019
ATS/IDSA guidelines, the risk factors for PA
are presented as risk factors for culture-
positive PA. Because the clinical features and
Table 3. Drug susceptibility of PA
Variable Definitive PA (n 5 25) Indeterminate PA (n 5 131)
Pansusceptible 20 (80) 116 (89)
Drug-resistant PA 4 (16) 8 (6)
MDR PA* 0 (0) 4 (3)
Carbapenem-resistant PA† 0 (0) 1 (1)
Definition of abbreviations: MDR 5 multidrug-resistant; PA 5 Pseudomonas aeruginosa.
Data are presented as n (%).
*MDR PA was also classified as drug-resistant PA.
†Carbapenem-resistant PA was also classified as MDR PA and drug-resistant PA.
Table 2. The treatments and prognoses of patients with definitive PA, indeterminate PA, and non-PA pneumonia
Variable Definitive PA Pneumonia aOR (95% CI) Indeterminate PA Pneumonia aOR (95% CI)
Hospitalization 1.09 (0.43–2.73) 2.36 (1.40–3.97)
Treatment
Antipseudomonal drug 12.22 (4.45–33.56) 3.53 (2.37–5.25)
Two antipseudomonal drugs 19.87 (3.64–108.53) 2.26 (0.47–10.88)
Respirator 5.40 (1.96–14.84) 1.35 (0.67–2.72)
Vasopressor 5.11 (1.52–15.34) 0.83 (0.30–2.29)
Treatment duration .10 d 2.65 (1.19–5.89) 3.17 (2.19–4.60)
Treatment failure 2.66 (0.89–7.96) 3.34 (2.07–5.39)
Mortality
14-d mortality 13.04 (4.42–38.51) 1.35 (0.59–3.11)
30-d mortality 9.89 (3.67–26.66) 1.78 (0.94–3.36)
Definition of abbreviations: aOR 5 adjusted odds ratio; CI 5 confidence interval; PA 5 Pseudomonas aeruginosa.
Multinomial logistic regression models were used to explore the clinical factors associated with the three groups (definitive PA, indeterminate
PA, and non-PA pneumonia). For comparisons between definitive PA and non-PA pneumonia and between indeterminate PA and non-PA
pneumonia, non-PA pneumonia was used as a baseline group. The model was adjusted for age, sex, nursing home residency, chronic
obstructive pulmonary disease, past history of pneumonia, and CURB-65 scores (Confusion, Urea .7 mmol/l, Respiratory rate >30/min, low
systolic (,90 mm Hg) or diastolic (<60 mm Hg) Blood pressure, age >65 years). CURB-65 scores was calculated and one point given for each
feature present.
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mortality rates vary between definitive PA
and indeterminate PA pneumonia, risk
factors for PA pneumonia should be
specified for only definitive PA pneumonia,
and the proportions of definitive PA and
indeterminate PA pneumonia should be
locally validated in each area.
Patients with definitive PA pneumonia
were more likely to have a history of
tuberculosis and COPD/bronchiectasis than
patients with non-PA pneumonia. This
finding is compatible with the results of
previous studies (5, 9). PA tends to colonize
the injured lower respiratory tract, such as in
patients with COPD/bronchiectasis and
tuberculosis. PA was isolated from sputum in
4–15% of patients with COPDwithout
pneumonia (16). In the current study, a
strong association with chronic lung diseases
was observed for definitive PA pneumonia.
This result indicates that chronic lung
diseases increase the risk of PA infection.
Although a similar trend was also observed
in patients with indeterminate PA
pneumonia, patients with indeterminate PA
pneumonia were more likely to be clinically
frail than patients with non-PA pneumonia.
This result suggests that, among patients
with indeterminate PA pneumonia, the
clearance of PA from the airway and an
adequate host response to PAmay be
reduced in older adults (17).
In the current study, a quarter of the
patients with non-PA pneumonia were
initially treated with antipseudomonal drugs
for a median of 6 days (interquartile range,
3–8 d), and treatment was de-escalated in
only 21% of these patients. Althoughmore
than half of the patients with indeterminate
PA pneumonia were treated with
antipseudomonal drugs, treatment was de-
escalated in 24%. Thus, antipseudomonal
drugs might be overused in patients with
indeterminate PA and non-PA pneumonia,
although some patients with indeterminate
PA potentially included pneumonia due to
PA or other antibiotic-resistant bacteria.
Clinicians may intend to target not only PA
but also other atypical organisms or
antibiotic-resistant bacteria with an
antipseudomonal drug. Clinicians should
note that the mortality rate was lower among
patients with indeterminate PA pneumonia
than among patients with definitive PA
pneumonia in the acute phase. In an aging
society, the proportion of patients with
indeterminate PA pneumonia, including frail
older adults, will increase.With respect to
antimicrobial resistance, monitoring
antimicrobial use is required not only for
patients with non-PA pneumonia but also for
patients with indeterminate PA pneumonia
and should be employed to effectively reduce
the usage of antipseudomonal drugs in the
latter population.
Adequate de-escalation of antibiotics
based on culture and Gram staining results is
essential to reduce the drug resistance because
the use of antipseudomonal b-lactam
antibiotics leads to new drug resistance (18).
Combining with a scoring system that has a
high negative predictive value (19), Gram
stain–guided empirical therapy is also useful
for limiting the use of antipseudomonal
drugs. Taniguchi and colleagues (20) reported
that a Gram stain reduced the overuse of
broad-spectrum antimicrobials and drug
costs. A Gram stain is recommended only for
adequate specimens, which are sometimes
difficult to obtain (7). Thus, new tools in
addition to Gram staining are needed to
differentiate definitive PA from indeterminate
PA pneumonia specifically and de-escalate
adequately.
The proportion of MDR PAwas lower
in this study than in previous studies. In our
study, the proportions of MDR PAwere 0%
(n5 0/25) and 3.1% (n5 4/131) in the
definitive PA and indeterminate PA groups,
respectively. However, the proportion of
MDR PA was reported to be 32% (n5 22/
68) by Cilloniz and colleagues (5) and 24.8%
(n5 33/133) by Restrepo and colleagues
(15). The difference may be dictated by area
because more than half of the MDR PA cases
in one multicenter study were reported in
Europe (15). Because the proportion of MDR
PA varies by country, local data are needed,
as proposed in the ATS/IDSA 2019
guidelines. The treatment of PA pneumonia
with two antipseudomonal drugs should be
considered only in areas with a high
proportion of MDR PA.
The present study has some limitations.
First, we included patients in only two
hospitals, and the average Japanese hospital
may have thus not been represented.
According to the Japan Nosocomial
Infections Surveillance, MDR PA was rarely
isolated (0.03%) in hospital patients in Japan
in 2014; this finding of a low proportion of
MDR PA is in line with our findings. Second,
we intended to establish the true burden of
definitive PA pneumonia, but no
standardized criteria exist for distinguishing
between definitive and indeterminate PA
pneumonia. Thus, we used stringent criteria
based on the Gram staining and culture
results. Potential bias exists because patients
with definitive PA pneumonia may be able to
expectorate good sputum samples, whereas
patients with indeterminate PA pneumonia
may not be able to expectorate sputum.
Likewise, a good sputum sample is more
readily available from an intubated patient.
Third, we evaluated clinical factors associated
with PA infection using multinomial
regression adjusted for potential
confounders. However, because of the
limited sample size, the 95% confidence
intervals of our effect estimates require
careful interpretation considering the
multiple comparisons. Thus, a further study
with a larger sample size is needed.
In conclusion, the prevalence of
definitive PA pneumonia among patients
with CAP was low, and the clinical features
and outcomes were considerably different
among the PA categories. The establishment
of stringent criteria for diagnosing CAP is
needed to avoid prescribing unnecessary
antipseudomonal drugs.
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